ImmunoGen, Inc. Announces Presentations at Upcoming AACR Annual Meeting 2015
March 19 2015 - 08:00AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced the presentations on
Company and partner programs to be made at the upcoming American
Association for Cancer Research (AACR) annual meeting to be held
April 18-22, 2015 in Philadelphia, PA. These presentations will
feature scientific data for ImmunoGen and partner ADCs as well as
an array of ImmunoGen technology innovations.
“The presentations on ADCs by ImmunoGen researchers and our
partners at AACR this year illustrate our ongoing commitment to
advancing the ADC field to achieve better therapies for people with
cancer,” commented Daniel Junius, President and CEO. “The topics
span research in support of our IMGN853 and IMGN779 product
candidates, preclinical data for five partner ADCs, and some of the
findings from our research related to site-specific payload
attachment to antibodies.”
Presentations Related to ImmunoGen, Partner ADCs
- “Development and application of an
immunohistochemistry-based clinical assay for evaluating Folate
Receptor Alpha (FRα) expression in a phase I clinical trial of
IMGN853.” Abstract number: 4357
- “Plasma pharmacokinetics and tumor
accumulation in mice of IMGN779, an antibody-drug conjugate for
acute myeloid leukemia.” Abstract number: 4504
- “In vitro and in vivo activity of a
highly potent and novel FGFR2/FGFR4 dual targeting antibody-drug
conjugate.” Abstract number:1680
- “Development and activity of a novel
antibody-drug conjugate for the treatment of P-cadherin expressing
cancers.” Abstract number: 1682
- “A novel anti-CEACAM5
maytansinoid-antibody-drug conjugate for the treatment of
colorectal, lung and gastric tumors.” Abstract number: 1688
- “Generation of a novel
maytansinoid-antibody-drug conjugate targeting LAMP1 expressed on
the surface of tumor cells.” Abstract number: 1689
- “Development of a novel antibody-drug
conjugate for the treatment of c-Kit expressing solid tumors and
AML.” Abstract number: 1695
- “A c-Kit targeting antibody-drug
conjugate is efficiently metabolized and activated inside cancer
cell lines and xenograft tumors.” Abstract number: 5325
Presentations by ImmunoGen Scientists on ADC Technology
Innovations
Site-specific linkage; payload molecules/antibody – benefit
assessment, novel approaches
- “Stability and efficacy comparison of
site-specific and lysine-linked maytansinoid antibody-drug
conjugates.” Abstract number: 645
- “SeriMabs: N-terminal serine
modification enables modular, site-specific payload incorporation
into antibody-drug conjugates (ADCs).” Abstract number: 647
- “Antibody-drug conjugates: engineered
N-terminal serine residues as a novel approach for site-specific
conjugation.” Abstract number: 653
- “Effects of drug load on therapeutic
index for antibody-maytansinoid conjugates.” Abstract number:
4531
Expanding portfolio of novel payload agents
- “Antibody-drug conjugates (ADCs) of
indolino-benzodiazepine DNA-alkylating agents.” Abstract number:
652
Advancing ADC screening methodologies
- “Microscale methods for preparation and
screening of antibody-drug conjugates.” Abstract number: 5442
Additional information – including abstracts and presentation
schedule – can be found at www.aacr.org
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The
Company’s ADC technology uses tumor-targeting antibodies to deliver
an ImmunoGen cell-killing agent specifically to cancer cells; the
Company has also developed antibodies with anticancer activity of
their own. The first product with ImmunoGen’s ADC technology is
Roche’s Kadcyla®. ImmunoGen has three wholly owned product
candidates in clinical testing with additional compounds in
clinical testing through the Company’s partnerships with Amgen,
Bayer HealthCare, Biotest, Novartis and Sanofi. More information
about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
This press release includes forward-looking
statements. For these statements, ImmunoGen claims the protection
of the safe harbor for forward-looking statements provided by the
Private Securities Litigation Reform Act of 1995. It should be
noted that there are risks and uncertainties related to the
development of novel anticancer products, including risks related
to preclinical and clinical studies, their timings and results. A
review of these risks can be found in ImmunoGen’s Annual Report on
Form 10-K for the fiscal year ended June 30, 2014 and other reports
filed with the Securities and Exchange Commission.
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Pure Communications,
Inc.Dan Budwick, 973-271-6085
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Feb 2024 to Mar 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2023 to Mar 2024